Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRPORT amino acid infusion trial in lung transplantation
ACTRN12625001381471Phase 3Not yet recruiting
- Sponsor
- Alfred Health
- Start
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of Synthamin 17 in acute kidney failure (AKF) (2 arms), sponsored by Alfred Health. Primary endpoints: Consent rate and Protocol compliance rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Synthamin 17
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ACTRN12625001381471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001381471.